MOUNJARO® 7.5mg KwikPen®, 1 Stk.

MOUNJARO® 7.5mg KwikPen® provides a weekly subcutaneous injection of 7.5 mg tirzepatide in 0.6 mL. The device contains 30 mg in 2.4 mL (approx. 12.5 mg/mL) and is used in stepwise titration or as part of a maintenance plan. Its mechanism involves stimulating GIP and GLP-1 receptors to improve glucose control and support weight loss.

• Per dose: 7.5 mg tirzepatide (0.6 mL)

• Total content: 30 mg/2.4 mL

• Strength: 12.5 mg/mL

• Mode of action: GIP/GLP-1 dual agonist

• Subcutaneous injection areas: Abdomen, thigh, upper arm

Weekly dosing is the standard, with escalation guided by physician advice.

• Dose progression: Start 2.5 mg weekly; increase every 4 weeks; 7.5 mg is an escalation step

• Maintenance choices: 5 mg, 10 mg, 15 mg depending on tolerance and need

• Weekly injection: Same day each week; can shift day if ≥3 days apart

• Missed dose: ≤4 days → take ASAP; >4 days → skip

• Administration: Dial pen, inject 0.6 mL, hold 5 sec

• Rotate sites weekly

Used in the management of type 2 diabetes and as an adjunct in obesity treatment.

• For type 2 diabetes: As monotherapy or combination

• For weight management: BMI ≥30 or ≥27 with weight-related comorbidities

• Contraindications: Hypersensitivity to tirzepatide or excipients

• Warnings: Caution in patients with history of pancreatitis, severe gastroparesis, or proliferative retinopathy

• Pregnancy: Not recommended; discontinue if planning pregnancy

• Typical adverse effects: GI events, hypoglycaemia with insulin/SU, injection site irritation

Each weekly injection delivers 7.5 mg tirzepatide.

• Dose: 7.5 mg tirzepatide per 0.6 mL

• Total pen content: 30 mg/2.4 mL

• Concentration: 12.5 mg/mL

• Excipients: Contains benzyl alcohol; minimal sodium

• Appearance: Clear to light yellow solution

The packaging includes the medicine pen and patient materials.

• KwikPen device: Delivers 4 fixed doses

• Printed material: PIL + Instructions for Use

• Needles: Must be purchased separately

Adverse effects are in line with other doses, with gastrointestinal issues most common.

• GI symptoms: Up to 33% nausea, diarrhoea, constipation during dose escalation

• Injection-site reactions: Mild to moderate, ≤6%

• Hypoglycaemia risk: Particularly with insulin or secretagogues

• Gallbladder issues: ~1–2%

• Rare: Pancreatitis, allergic reactions

Storage instructions match those of other dose strengths.

• Refrigerate unused pens (2–8°C)

• Never freeze

• After first injection: Store ≤30°C, discard after 30 days

• After 4 doses: Dispose of pen safely

• Remove and discard needles after each use